Allergan launches Crestor generic in the US
pharmafile | May 3, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the first company to launch a generic of the drug in the US.
Crestor has consistently been one of the highest selling in the drugs in the US, but went off patent earlier this year. It is a member of the drug class of statins, used with a combination of lifestyle factors to treat high cholesterol and related conditions, as well prevent cardiovascular disease.
According to data from IMS Health, Crestor generated sales of $6.5 billion, in the US alone, for the 12 months to March 31 2016.
Allergan has launched its generic version of Crestor according to an agreement struck with AstraZeneca on March 25 2013, and 67 days prior to the expiration of paediatric exclusivity in July.
Robert Stewart, executive VP of generics and global operations at Allergan, says: “This first-to-market launch demonstrates the talent of our generics team in developing, manufacturing and bringing to market high-quality, affordable versions of widely used medicines like Crestor. This is expected to be the largest generic launch in 2016, benefitting patients and reducing cost for US health systems.”
Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for …
Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …
Alladapt Immunotherapeutics has announced that ADP101 has received Fast Track Designation from the US Food …